Clinical trials
catalyst calendar across sponsors →Studies where AVR is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
6 interventional
Held by 8 tracked-famous managers (CITADEL ADVISORS LLC, RENAISSANCE TECHNOLOGIES LLC, Balyasny Asset Management L.P., Holocene Advisors, LP, AQR CAPITAL MANAGEMENT LLC, +3 more) · FINRA short interest 6.9 days to cover (settled 2026-07-31) · insider 90d: 1 buys / 0 sells · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| DurAVR™ THV System: EMBARK StudyNCT05182307DurAVR™ prosthetic heart valve implantOpen-label · Device feasibility | Not applicable | Active, not recruiting | Device: DurAVR™ THV System | Symptomatic Aortic Stenosis, Severe Aortic Valve Stenosis, Aortic Valve Calcification | 150 | Jan 2028 | ≤ 530 d | 2026-06-26 |
| A Clinical Trial Assessing the Safety and Effectiveness of the DurAVR® THV SystemNCT07194265Composite of all-cause mortality, all stroke and cardiovascular hospitalizationRandomized · Single-masked · Treatment | Not applicable | Recruiting | Device: TAVR with DurAVR® THV, TAVR with SAPIEN THV series or the Evolut THV series | Severe Aortic Stenosis, Valve-in-valve Procedures | 1,650 | Dec 2027 | ≤ 499 d | 2026-07-15 |
| DurAVR™ THV EU-EFSNCT06510855All-cause mortality or disabling strokeNon-randomized · Open-label · Device feasibility | Not applicable | Active, not recruiting | Device: DurAVR™ THV System | Symptomatic Aortic Stenosis, Severe Aortic Valve Stenosis, Aortic Valve Calcification, Aortic Valve Failure, Aortic Valve Disease | 40 | Jul 2026 | — | 2026-05-04 |
| Use of DurAVR™ THV System in Subjects With Severe Aortic Stenosis: Early Feasibility StudyNCT05712161All-cause mortality or disabling strokeOpen-label · Device feasibility | Not applicable | Active, not recruiting | Device: DurAVRTM THV System | Aortic Stenosis, Symptomatic Aortic Stenosis, Severe Aortic Valve Stenosis, Aortic Valve Calcification | 15 | 2023-12-29actual | — | 2026-06-26 |
| First in Human Feasibility Study With ADAPT 3D - ALR for Aortic Leaflet RepairNCT04178213mean pressure gradient (mmHg) across the valve (less than 20 mmHg)Open-label · Treatment | Not applicable | Unknown status | Device: Implantation of ADAPT 3D ALR | Aortic Stenosis, Aortic Insufficiency | 15 | Jun 2022 | — | 2022-02-16 |
| CardioCel Tri-leaflet Repair StudyNCT02629328In-hospital survival (defined as percentage of patients alive and discharged from the index operation - presented as the inverse, or standard surgical operative mortality)Open-label · Treatment | Not applicable | Completed | Device: CardioCel | Aortic Stenosis, Aortic Insufficiency | 28 | 2017-07-05actual | — | 2019-01-29 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19